论文部分内容阅读
目的:探讨思密达联合甲硝唑治疗重症腹泻的临床疗效。方法:将我院2009年7月—2011年9月收治的重症腹泻患者80例随机分为对照组与治疗组,每组40例,对照组给予思密达+生理盐水保留灌肠治疗,治疗组采用思密达+甲硝唑注射液保留灌肠治疗。观察两组治疗后的临床疗效、止泻时间以及不良反应发生情况。结果:治疗组显效率和总有效率均明显高于对照组(P<0.05);治疗组止泻时间明显短于对照组(P<0.05);两组不良反应发生率比较差异无统计学意义(P>0.05)。结论:思密达联合甲硝唑治疗重症腹泻临床疗效确切,止泻时间短,不良反应小,值得推广应用。
Objective: To investigate the clinical efficacy of metmin combined with metronidazole in the treatment of severe diarrhea. Methods: 80 cases of severe diarrhea admitted to our hospital from July 2009 to September 2011 were randomly divided into control group and treatment group, 40 cases in each group. The control group was treated with Smecta + saline retention enema, and the treatment group Smectite + metronidazole injection retention enema treatment. The clinical efficacy, antidiarrheal time and incidence of adverse reactions in both groups were observed. Results: The effective rate and total effective rate in the treatment group were significantly higher than those in the control group (P <0.05). The antidiarrheal time in the treatment group was significantly shorter than that in the control group (P <0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). Conclusion: Smectite metronidazole combined with metronidazole in the treatment of severe diarrhea has definite curative effect, short antidiarrheal time and small adverse reactions, which is worth popularizing and applying.